San Diego-dependent Viking Therapeutics marked alone as a significant competitor while in the weight loss drug current market in February following revealing promising data from a mid-stage trial of experimental drug VK2735, which instructed it rivaled—and outperformed—Novo and Lilly drugs when given as being a weekly injection and in March the